Wisconsin Alumni Research Foundation

Cellsnap LLC

University of California

Other

The Scripps Research Institute

The Medical College of Wisconsin, Inc.

William Howard Tepp

Eric Arthur Johnson

Sabine Pellett

Marite Bradshaw

Joseph T Barbieri

Tony L Yaksh

Michael C Goodnough

Qinghao Xu

Guangyun Lin

Marc Marino

Christina Pier

David James Beebe

Gary E Borodic

Raymond C Stevens

Carl J Malizio

Michael Baldwin

Amanda Przedpelski

Mark Joseph Jacobson

Christina L Pier

Pal Erik Gustav Stenmark

Amy Paguirigan

Regina Clare Meyer Whitemarsh

Regina Clare Whitemarsh

Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.

Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms

The present disclosure relates to neurotoxins and uses thereof. In particular, provided herein are botulinum neurotoxins with altered properties and uses thereof (e.g., research, screening, and therapeutic uses).

Neurotoxins and uses thereof

The present disclosure relates to chimeric neurotoxins and uses thereof. In particular, provided herein are chimeric botulinum neurotoxins with altered properties and uses thereof (e.g., research, screening, and therapeutic uses).

Hybrid neurotoxins and uses thereof

A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.

Regulation of specific spinal neurons regulating pain transmission via chimeric toxins

Preparations ofneurotoxin BoNT/A3 and methods for using such preparations for treating a patient having a symptom in need of botulinum toxin therapy are provided herein.

Purification, characterization, and use of Clostridium botulinum neurotoxin BoNT/A3

The present invention relates to compositions and methods for testing agents (e.g.,neurotoxin (BoNT) detection and analysis). In particular, the present invention relates to the use of Human induced pluripotent stem (hiPS) derived cells for agent detection and analysis.

Compositions and methods for toxigenicity testing

A highly sensitive method of analyzing a sample for the presence or activity of botulinum neurotoxin (BoNT) or antibodies specific for botulinum neurotoxin is disclosed. In one embodiment, the method comprises the steps of preparing primary non-human mammalian or avian spinal cord cells, and exposing the cells to a test sample, in parallel with a control sample, and examining the extent of cleavage of the intracellular neuronal target protein in both the test and control sample.

Method of detecting botulinum neurotoxin and antibodies that neutralize botulinum neurotoxin action

A novel subtype of type A botulinum neurotoxin (BoNT/A) is disclosed in the application. Methods to purify the neurotoxin as well as uses thereof are also disclosed.

[object Object]

A method of producing botulinum toxin C-terminal receptor binding domain (HCR) is disclosed. The one embodiment, the method comprises the steps of (a) preparingtransformed with an expression vector comprising DNA encoding HCR protein, (b) inducing expression of the HCR protein at a reduced temperature in a culture media, and (c) purifying the HCR protein via extraction, wherein the extraction comprises a clarification by centrifugation and a filtration, wherein the purified HCR protein is at least 10 mg/L of culture medium.

A method of targeting therapeutic molecules to motor neurons is disclosed. In one embodiment, this method comprises the steps of (a) synthesizing a prodrug comprising a therapeutic molecule covalently bound to a polymeric delivery vehicle, and (b) conjugating the prodrug to a botulinum neurotoxin heavy chain.

Method of targeting pharmaceuticals to motor neurons

A hybrid botulinal neurotoxin is disclosed. In one embodiment, the neurotoxin comprises a combination of a botulinal neurotoxin heavy chain and light chain, wherein the light chain and heavy chain are not of the same serotype and wherein the heavy and light chains are linked by a homobifunctional sulfydryl linker. A method for creating hybrid neurotoxins comprised of different functional domains is also disclosed.

Growing community of inventors

Stoughton, WI, United States of America

William Howard Tepp